TR201914406A2 - SOLID ORAL PHARMACEUTICAL FORMULATIONS CONTAINING SAPROPTERIN DIHYDROCHLORIDE AND AT LEAST ONE PHARMACEUTICAL EXCIPIENT - Google Patents

SOLID ORAL PHARMACEUTICAL FORMULATIONS CONTAINING SAPROPTERIN DIHYDROCHLORIDE AND AT LEAST ONE PHARMACEUTICAL EXCIPIENT Download PDF

Info

Publication number
TR201914406A2
TR201914406A2 TR2019/14406A TR201914406A TR201914406A2 TR 201914406 A2 TR201914406 A2 TR 201914406A2 TR 2019/14406 A TR2019/14406 A TR 2019/14406A TR 201914406 A TR201914406 A TR 201914406A TR 201914406 A2 TR201914406 A2 TR 201914406A2
Authority
TR
Turkey
Prior art keywords
formulations containing
solid oral
sapropterin dihydrochloride
pharmaceutical formulations
pharmaceutical
Prior art date
Application number
TR2019/14406A
Other languages
Turkish (tr)
Inventor
Palantöken Arzu
Türkoğlu Damla
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2019/14406A priority Critical patent/TR201914406A2/en
Priority to EP20868515.6A priority patent/EP4034120A4/en
Priority to PCT/TR2020/050688 priority patent/WO2021061065A1/en
Publication of TR201914406A2 publication Critical patent/TR201914406A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş, sapropterin dihidroklorür ve en az bir farmasötik eksipiyan içeren katı oral farmasötik formülasyonlarla ilgilidir.The present invention relates to solid oral pharmaceutical formulations containing sapropterin dihydrochloride and at least one pharmaceutical excipient.

TR2019/14406A 2019-09-23 2019-09-23 SOLID ORAL PHARMACEUTICAL FORMULATIONS CONTAINING SAPROPTERIN DIHYDROCHLORIDE AND AT LEAST ONE PHARMACEUTICAL EXCIPIENT TR201914406A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2019/14406A TR201914406A2 (en) 2019-09-23 2019-09-23 SOLID ORAL PHARMACEUTICAL FORMULATIONS CONTAINING SAPROPTERIN DIHYDROCHLORIDE AND AT LEAST ONE PHARMACEUTICAL EXCIPIENT
EP20868515.6A EP4034120A4 (en) 2019-09-23 2020-08-05 Solid oral pharmaceutical formulations comprising sapropterin dihydrochloride and at least one pharmaceutical excipient
PCT/TR2020/050688 WO2021061065A1 (en) 2019-09-23 2020-08-05 Solid oral pharmaceutical formulations comprising sapropterin dihydrochloride and at least one pharmaceutical excipient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2019/14406A TR201914406A2 (en) 2019-09-23 2019-09-23 SOLID ORAL PHARMACEUTICAL FORMULATIONS CONTAINING SAPROPTERIN DIHYDROCHLORIDE AND AT LEAST ONE PHARMACEUTICAL EXCIPIENT

Publications (1)

Publication Number Publication Date
TR201914406A2 true TR201914406A2 (en) 2021-04-21

Family

ID=75167064

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/14406A TR201914406A2 (en) 2019-09-23 2019-09-23 SOLID ORAL PHARMACEUTICAL FORMULATIONS CONTAINING SAPROPTERIN DIHYDROCHLORIDE AND AT LEAST ONE PHARMACEUTICAL EXCIPIENT

Country Status (3)

Country Link
EP (1) EP4034120A4 (en)
TR (1) TR201914406A2 (en)
WO (1) WO2021061065A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202201356D0 (en) * 2022-02-02 2022-03-16 Meta Healthcare Ltd Sapropterin formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2436379A1 (en) * 2004-11-17 2012-04-04 BioMarin Pharmaceutical Inc. Stable tablet formulation
CA2828685C (en) * 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
WO2012127431A1 (en) * 2011-03-24 2012-09-27 Rubicon Research Private Limited Stabilized compositions of tetrahydrobiopterin
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin

Also Published As

Publication number Publication date
EP4034120A1 (en) 2022-08-03
WO2021061065A1 (en) 2021-04-01
EP4034120A4 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
MA41265B1 (en) Compositions for administration of ileo-jejunal drugs.
GEP20237506B (en) Pcsk9 antagonist compounds
MD3442972T2 (en) Bromodomain inhibitors
CL2017003320A1 (en) Pharmaceutical formulations containing tenofovir and emtricitabine
CY1122024T1 (en) NOTCH PATHWAY SIGNALING INHIBITING COMPOUNDS
BR112016019592A8 (en) COMPOUND, USE OF A COMPOUND, AND, PHARMACEUTICAL COMPOSITION
BR112017028140A2 (en) pharmaceutical formulations
EA201991700A1 (en) SELECTIVE INHIBITORS JAK1
JOP20210305A1 (en) Imatinib formulations, manufacture, and uses thereof
CY1120530T1 (en) BY ORAL ADMINISTRATIVE PHARMACEUTICAL COMPOSITION
CY1115556T1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES DAVIGATRAN
MX2019001042A (en) Piperidine cxcr7 receptor modulators.
CY1122473T1 (en) HIGH DOSE OPTIMIZED MID-SALIZED TABLET
EA202191955A1 (en) MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS
EA201991287A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS BASED ON TIKAGRELOR FOR ORAL USE
EA201200485A1 (en) ORAL FALLING PHARMACEUTICAL DRUG FORM CONTAINING AIPIPRAZOL
TR201721505A2 (en) The combination comprising linagliptin and metformin
BR112018071363A2 (en) oral nicotinamide pharmaceutical compositions
TR201009394A2 (en) Improved montelukast formulations.
TR201914406A2 (en) SOLID ORAL PHARMACEUTICAL FORMULATIONS CONTAINING SAPROPTERIN DIHYDROCHLORIDE AND AT LEAST ONE PHARMACEUTICAL EXCIPIENT
BR112017024126B8 (en) PHARMACEUTICAL COMPOSITIONS, MICRONIZED COMPOUND A AND/OR AT LEAST ONE MICRONIZED PHARMACEUTICALLY ACCEPTABLE SALT OF COMPOUND A AND USE THEREOF
TR201721700A2 (en) DISTRIBUTED FORMULATIONS OF SAXAGLIPT IN THE MOUTH
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
TR200903014A1 (en) Orally dispersed dimebolin compounds.
EA201991286A1 (en) A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN